SyneuRx CEO Emil Tsai Named Fellow of National Academy of Inventors

Renowned Johns Hopkins and Harvard-educated neuroscience and brain disorder expert is being inducted as a 2022 fellow from prestigious organization that encourages inventors in academia

Press Release

Dec 08, 2022

LOS ANGELES and NEW TAIPEI CITY, Taiwan, Dec. 8, 2022 – SyneuRx™ International (TPEX:6575) Founder, Chairman and Chief Executive Officer Emil Tsai, M.D., Ph.D., M.A.S., has been selected as a National Academy of Inventors (NAI) fellow for the class of 2022 for his work in pioneering the science of regulating the main neurotransmitters in central nervous system disorders, such as schizophrenia, depression and dementia.

The highly prestigious award honors inventors who have demonstrated remarkable innovation-producing technologies that have brought or aspire to bring a real impact on the quality of life, economic environment, and welfare of society. Election as an NAI fellow is the highest professional distinction specific to academic inventors.

So far, the NAI program has 1,567 fellows worldwide representing more than 300 prestigious universities and governmental and non-profit research institutes. Among all NAI fellows, there are 165 presidents and senior leaders of research universities, governmental and non-profit research institutes; about 642 members of the National Academies of Science, Engineering and Medicine; about 45 inductees of the National Inventors Hall of Fame; 63 recipients of the U.S. National Medal of Technology and Innovation and U.S. National Medal of Science; and 45 Nobel Laureates. NAI fellows collectively hold more than 53,000 U.S. patents, which have created more than one million jobs. In addition, over $3 trillion in revenue has been generated based on NAI fellow discoveries.

“The work SyneuRx is doing is having a real impact on people’s lives,” said Tsai. “Election to the rank of NAI fellow honors and recognizes the important progress our team’s decades-long research is making for patients suffering from disorders such as schizophrenia, dementia, and depression, as well as H1N1 influenza and COVID-19.”


The honor caps an impressive year for Tsai and SyneuRx, who begins marketing Tanquilynne® a proprietary health supplement for lung health, in Singapore, recently named renowned neuroscientist Dr. Joseph T. Coyle chairman of SyneuRx’s Scientific Advisory Board, and announced positive results from SyneuRx’s phase 2 clinical trial evaluating the efficacy and safety of SNB01 (Pentarlandir®), a novel COVID-19 oral antiviral candidate that has promise to treat the COVID-flu “twindemic.”


“On behalf of the 2022 National Academy of Inventors Fellows Selection Committee and Board of Directors, we are very pleased to inform Dr. Tsai of his election to the rank of NAI Fellow,” NAI President Paul R. Sanberg remarked in a letter notifying Tsai of the award. “Our sincere congratulations on this well-deserved recognition of your accomplishments, and it is an honor to welcome you as a Fellow. I look forward to working with you in support of NAI’s mission to promote the importance of innovation and the celebration of academic invention.”


Tsai and the rest of the 2022 fellows will be inducted on June 27, 2023, during the NAI 12th Annual Meeting in Washington, D.C.


For more information about SyneuRx, visit

About SyneuRx

SyneuRx International (TPEX:6575) is a multinational bio-pharmaceutical research laboratory focused on developing new classes of drugs for COVID-19 and multiple major central nervous system (C.N.S.) disease conditions. Founded in 2013, SyneuRx is poised to bring change-making pharmaceuticals to market with a robust, promising pipeline of seven investigational drugs for C.N.S. disorders and two for COVID-19 – eight of which are currently in phase 2 and phase 3 clinical trials with the U.S. Food and Drug Administration. The company’s mission is to infuse a scientific and humanistic approach into its research and development of safe, effective, and accessible therapies for patients suffering from disorders such as schizophrenia, dementia, depression, COVID-19 and other RNA-encoded viruses. Dedicated to taking a safety-first approach with its research and development by focusing on well-established lead compounds, natural sources, and plant substances to treat or prevent illness, SyneuRx has received Breakthrough Therapy Designations and Orphan Drug Designations from the F.D.A. for two of its novel C.N.S. therapeutics. To learn more, visit

Media Contact

SyneuRx Press Office

Phone: (818) 696-8800